More on IBIO
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $1.51 |
|
|||
| Open | $1.48 | ||||
| 52 Wk High | $0.80 | ||||
| 52 Wk Low | $0.34 | ||||
| Day High | $1.56 | ||||
| Day Low | $1.45 | ||||
| P/E | N/A | ||||
| EPS | $-0.08 | ||||
| Volume | 1,072,374 | ||||
- Form 8-K iBio, Inc. For: Jul 01
- iBio reports preclinical data on IBIO-610 Activin E antibody in obese NHPs
- iBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP Study
- Raymond James Starts iBio, Inc. (IBIO) at Outperform
- B.Riley Starts iBio, Inc. (IBIO) at Buy
- iBio to Participate in Upcoming Healthcare Investor Conferences
- iBio begins phase 1 trial of obesity drug IBIO-600
- iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity
- Form 4 iBio, Inc. For: May 18 Filed by: Stoner Elizabeth
- Form SCHEDULE 13G/A iBio, Inc. Filed by: Logos Global Management LP
Entities mentioned with IBIO
- Earnings | View Related Stories »
- Definitive Agreement | View Related Stories »
- FDA | View Related Stories »
- 13G | View Related Stories »
- Pre Market Movers | View Related Stories »
- S3 | View Related Stories »
- Pre-Open Losers | View Related Stories »
- Pre-Open Winners | View Related Stories »
- Show More...
